You are here

Article Text

Article menu
Download PDFPDF
Matters arising
Treatment with calcitonin for osteoporosis
  1. MOÏSE AZRIA
  1. R and D Division, Calcitonin Biology and Safety Group, Novartis Pharma AG, PO Box,Basle, Switzerland

https://doi.org/10.1136/ard.56.7.440

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    I would like the opportunity to correct, or possibly update, a number of the facts concerning calcitonin contained in Dr Patel’s comprehensive review article on drug treatments for osteoporosis.1

    He states that nasal preparations of calcitonin are licensed for use in osteoporosis in ‘some European countries and Japan’, whereas in fact the nasal spray formulation of salmon calcitonin developed at Sandoz (now Novartis) is currently approved in more than 70 countries worldwide, including the USA and almost all the countries of Europe. Japan, …

    View Full Text

    Linked Articles